Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Real-world outcomes of talquetamab in Relapsed/Refractory multiple myeloma

Blood (2025) 146 (Supplement 1): 4051.

https://doi.org/10.1182/blood-2025-4051

Published: 2025

Journal Articles

Real-world efficacy outcomes of epcoritamab and glofitamab in Relapsed/Refractory aggressive B-cell lymphoma: A single-center cohort emphasizing trial-ineligible populations

Yumeng Zhang, Fatima Tuz Zahra, Daniel DeAvila, Bijal Shah, Sameh Gaballa, Celeste Bello, Hayder Saeed, Abu-Sayeef Mirza, Leidy Isenalumhe, Omar Alexis Castaneda Puglianini, Aleksandr Lazaryan, Lubomir Sokol, Frederick Locke, Michael Jain, Zachary Thompson, Javier Pinilla-Ibarz, Julio Chavez

Blood (2025) 146 (Supplement 1): 2767.

https://doi.org/10.1182/blood-2025-2767

Published: 2025

Journal Articles

Toxicity profile of epcoritamab and glofitamab in aggressive B-cell lymphoma: A real-world analysis of CRS and icans in a single-center cohort

Yumeng Zhang, Daniel DeAvila, Fatima Tuz Zahra, Bijal Shah, Sameh Gaballa, Celeste Bello, Hayder Saeed, Leidy Isenalumhe, Lubomir Sokol, Michael Jain, Zachary Thompson, Javier Pinilla-Ibarz, Julio Chavez

Blood (2025) 146 (Supplement 1): 8017.

https://doi.org/10.1182/blood-2025-8017

Published: 2025

Journal Articles

Beyond chip: Ccrs predicts prolonged cytopenias and inferior survival following anti-BCMA CAR-T in multiple myeloma

Blood (2025) 146 (Supplement 1): 930.

https://doi.org/10.1182/blood-2025-930

Published: 2025

Journal Articles

Bridging therapy response and low pre-lymphodepletion plasma cell burden are associated with improved safety and efficacy outcomes of ciltacabtagene autoleucel in multiple myeloma

Blood (2025) 146 (Supplement 1): 2214.

https://doi.org/10.1182/blood-2025-2214

Published: 2025

Journal Articles

Oral Care™ kit as a prophylaxis for talquetamab-associated toxicities in patients with Relapsed/Refractory multiple myeloma

Blood (2025) 146 (Supplement 1): 7574.

https://doi.org/10.1182/blood-2025-7574

Published: 2025

Journal Articles

ClonoSEQ MRD negativity at day 90 is a strong predictor for progression-free and overall survival after BCMA-directed CAR T-cell therapy for relapsed multiple myeloma.

Blood (2025) 146 (Supplement 1): 5846.

https://doi.org/10.1182/blood-2025-5846

Published: 2025

Journal Articles

Real-world outcomes of elranatamab in relapsed/refreactor multiple myeloma: A single center analysis

Blood (2025) 146 (Supplement 1): 5833.

https://doi.org/10.1182/blood-2025-5833

Published: 2025

Journal Articles

Evolution of t(11;14) biology in multiple myeloma and it's role on outcomes to venetoclax treatment

Praneeth Reddy Sudalagunta, Filip Ionescu, Rafael Renatino Canevarolo, Daniel Deavila, Shrinjaya Thapa, Xiaohong Zhao, Mark Meads, Kenneth Shain, Rachid Baz, Ariel Grajales-Cruz, Ariosto Siqueira Silva

Blood (2025) 146 (Supplement 1): 5730.

https://doi.org/10.1182/blood-2025-5730

Published: 2025

Journal Articles

Impact of radiation in limited stage diffuse large B-cell lymphoma in the modern era

Juan Ramirez, Daniel DeAvila, Elisa Galdamez, Cynthia Gwede, Javier Pinilla-Ibarz, Yumeng Zhang, Julio Chavez

Blood (2025) 146 (Supplement 1): 1896.

https://doi.org/10.1182/blood-2025-1896

Published: 2025

Journal Articles

Dermatologic adverse effects with elranatamab mimicking talquetamab

M Bakri Hammami, Sean Haney, Daniel Deavila, Julia Fadul, Christine Simonelli, Samantha Seitzler, Sairekha Ravichandran, Melissa Alsina, Brandon Blue, Ariel Grajales-Cruz, Rachid Baz, Kenneth Shain

Blood (2025) 146 (Supplement 1): 2200.

https://doi.org/10.1182/blood-2025-2200

Published: 2025

Journal Articles

Genomics define neoplastic transformation in multiple myeloma precursor conditions

Blood (2025) 146 (Supplement 1): 686.

https://doi.org/10.1182/blood-2025-686

Published: 2025

Journal Articles

Real-time multimodal AI outperforms conventional scores for early risk prediction in BCMA CAR-T–Treated myeloma

Blood (2025) 146 (Supplement 1): 6140.

https://doi.org/10.1182/blood-2025-6140

Published: 2025

Update search

NARROW

Publications

Format

Article Type

Date

Availability

Real-world outcomes of talquetamab in Relapsed/Refractory multiple myeloma

Real-world efficacy outcomes of epcoritamab and glofitamab in Relapsed/Refractory aggressive B-cell lymphoma: A single-center cohort emphasizing trial-ineligible populations

Toxicity profile of epcoritamab and glofitamab in aggressive B-cell lymphoma: A real-world analysis of CRS and icans in a single-center cohort

Beyond chip: Ccrs predicts prolonged cytopenias and inferior survival following anti-BCMA CAR-T in multiple myeloma

Bridging therapy response and low pre-lymphodepletion plasma cell burden are associated with improved safety and efficacy outcomes of ciltacabtagene autoleucel in multiple myeloma

Oral Care™ kit as a prophylaxis for talquetamab-associated toxicities in patients with Relapsed/Refractory multiple myeloma

ClonoSEQ MRD negativity at day 90 is a strong predictor for progression-free and overall survival after BCMA-directed CAR T-cell therapy for relapsed multiple myeloma.

Real-world outcomes of elranatamab in relapsed/refreactor multiple myeloma: A single center analysis

Evolution of t(11;14) biology in multiple myeloma and it's role on outcomes to venetoclax treatment

Impact of radiation in limited stage diffuse large B-cell lymphoma in the modern era

Dermatologic adverse effects with elranatamab mimicking talquetamab

Genomics define neoplastic transformation in multiple myeloma precursor conditions

Real-time multimodal AI outperforms conventional scores for early risk prediction in BCMA CAR-T–Treated myeloma

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only